Fusen Pharmaceutical 過去の業績

過去基準チェック /06

Fusen Pharmaceuticalの収益は年間平均-63.6%の割合で減少していますが、 Pharmaceuticals業界の収益は年間増加しています。収益は年間5.7% 5.7%割合で増加しています。

主要情報

-63.6%

収益成長率

-63.6%

EPS成長率

Pharmaceuticals 業界の成長	5.6%
収益成長率	5.7%
株主資本利益率	-17.3%
ネット・マージン	-21.1%
前回の決算情報	30 Jun 2024

Recent updates

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

May 21

Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%

Mar 31

We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide

Feb 08

Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?

Jan 18

Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

Dec 28

What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition

Dec 07

If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns

Nov 20

収支内訳

Fusen Pharmaceutical の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

SEHK:1652 収益、費用、利益 ( )CNY Millions
日付	収益	収益	G+A経費	研究開発費
30 Jun 24	425	-90	188	98
31 Mar 24	496	-63	201	82
31 Dec 23	566	-36	214	65
30 Sep 23	614	-24	227	40
30 Jun 23	663	-11	216	39
31 Mar 23	577	-23	195	27
31 Dec 22	492	-35	173	15
30 Sep 22	414	-34	160	8
30 Jun 22	337	-34	146	0
31 Mar 22	361	-9	151	0
31 Dec 21	386	17	156	0
30 Sep 21	420	48	160	0
30 Jun 21	454	79	165	0
31 Mar 21	470	75	175	0
31 Dec 20	487	70	186	0
30 Sep 20	473	67	190	0
30 Jun 20	458	65	193	0
31 Mar 20	433	59	182	0
31 Dec 19	407	53	172	0
30 Sep 19	397	63	154	0
30 Jun 19	387	72	137	0
31 Mar 19	424	87	138	0
31 Dec 18	462	102	139	0
30 Sep 18	507	102	158	0
30 Jun 18	493	98	156	0
31 Mar 18	473	98	146	0
31 Dec 17	453	97	136	0
30 Sep 17	427	86	127	0
31 Dec 16	442	95	112	0
31 Dec 15	369	45	86	0

質の高い収益: 1652は現在利益が出ていません。

利益率の向上: 1652は現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 1652は利益が出ておらず、過去 5 年間で損失は年間63.6%の割合で増加しています。

成長の加速: 1652の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: 1652は利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 6.4% ) と比較することは困難です。

株主資本利益率

高いROE: 1652は現在利益が出ていないため、自己資本利益率 ( -17.28% ) はマイナスです。

Fusen Pharmaceutical 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

First half 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.022 profit in 1H 2023)

Fusen Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 29, 2024

Full year 2023 earnings released: CN¥0.05 loss per share (vs CN¥0.046 loss in FY 2022)

Fusen Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022)

First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022)

Recent updates

Eltrombopag Olamine Tablets Developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Obtains the Approval for Marketing from the National Medical Products Administration of China

Fusen Pharmaceutical Company Limited Announces Acceptance of Application for Consistency Evaluation of Nicardipine Hydrochloride Injection

First half 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.022 profit in 1H 2023)

Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2024

Fusen Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 29, 2024

Fusen Pharmaceutical Company's Subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces Acceptance of Clinical Trial Application for ``SY617''

New minor risk - Market cap size

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Fusen Pharmaceutical Company Limited, Annual General Meeting, May 28, 2024

CEO & Executive Director recently bought HK$224k worth of stock

Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Metformin Empagliflozin Tablets (I)

Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%

Full year 2023 earnings released: CN¥0.05 loss per share (vs CN¥0.046 loss in FY 2022)

Fusen Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022)

First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022)

Fusen Pharmaceutical Company Limited to Report Q2, 2023 Results on Aug 29, 2023

Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023

Executive Chairman recently bought HK$84k worth of stock

CEO & Executive Director recently bought HK$1.0m worth of stock

Full year 2022 earnings released: CN¥0.046 loss per share (vs CN¥0.022 profit in FY 2021)

Executive Chairman recently bought HK$1.1m worth of stock

Executive Chairman recently bought HK$918k worth of stock

CEO & Executive Director recently bought HK$375k worth of stock

Executive Chairman recently bought HK$791k worth of stock

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Executive Chairman recently bought HK$2.3m worth of stock

Less than half of directors are independent

CEO & Executive Director recently bought HK$2.2m worth of stock

Executive Chairman recently bought HK$2.0m worth of stock

CEO & Executive Director recently bought HK$2.0m worth of stock

CEO & Executive Director recently bought HK$658k worth of stock

CEO & Executive Director recently bought HK$79k worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

First half 2022 earnings released: CN¥0.01 loss per share (vs CN¥0.057 profit in 1H 2021)

Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Six Months Ended June 30, 2022

Fusen Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Fusen Pharmaceutical Company Limited to Report First Half, 2022 Results on Aug 29, 2022

CEO & Executive Director recently bought HK$157k worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

Fusen Pharmaceutical Company Limited Declares Final Dividend for the Year Ended 31 December 2021

Less than half of directors are independent

Investor sentiment improved over the past week

CEO & Executive Director recently bought HK$856k worth of stock

CEO & Executive Director recently bought HK$2.1m worth of stock

Investor sentiment deteriorated over the past week

First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.044 in 1H 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly

First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.044 in 1H 2020)

Investor sentiment deteriorated over the past week

Fusen Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2020

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.089 (vs CN¥0.067 in FY 2019)

Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly

Full year 2020 earnings released: EPS CN¥0.09 (vs CN¥0.067 in FY 2019)

Investor sentiment improved over the past week

Fusen Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns

New 90-day low: HK$4.17

We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide

Company Secretary has left the company

Fusen Pharmaceutical Company Limited Announces Executive Changes, with Effect from 29 January 2021

Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?

Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

Investor sentiment deteriorated over the past week

過去基準チェック /06